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Brief Cognitive Screening Tools for Primary Care Practice 
  
Abstract 
Early detection and diagnosis of Alzheimer’s disease and other cognitive impairment presents 
as a critical issue facing primary and specialty care providers in Washington State.  In order to 
address the gaps and challenges faced by providers, the Dementia Action Collaborative offers 
the current paper to provide information and guidance around early detection and diagnosis of 
memory loss and dementia, including Alzheimer’s disease. At the conclusion of this paper, 
providers should be able to identify indications and opportunities for detection, appropriate 




Alzheimer’s Disease (AD) is a neurodegenerative disorder that poses one of the most 
formidable healthcare challenges of the 21st century. Of the 5.5 million Americans currently 
diagnosed with AD, 5.1M are over the age of 65, a population expanding by 10,000 people 
every day (1). The financial burden of AD on the U.S. economy in 2015 alone is estimated to be 
$226 billion, a cost predicted to significantly swell in 
upcoming decades (2). A recent study by Kelley and 
colleagues (3) indicates the average total cost per 
descendent with dementia exceeds that of all other 
conditions, including heart disease and cancer. Emerging 
evidence also highlights the importance of early 
detection and accurate diagnosis in terms of improving 
management of comorbid conditions, reducing 
preventable hospitalizations and emergency room visits, 
clarifying wishes around end-of-life care and improving 
advance care planning (4). 
Early detection is a critical issue for treating Mild Cognitive Impairment (MCI) and dementia, 
including AD. Emerging research suggests that MCI may be slowed or cognition and function 
improved via modifying cardiovascular and other risk factors through interventions addressing 
diet, exercise, sleep and alcohol consumption (5-7). Additionally, treating depression and 
Fewer than half of all 
patients with dementia 
carry a diagnosis in their 
medical record.  
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monitoring and treating metabolic, vitamin and endocrine abnormalities (i.e., preventing 
hyperhomocysteine) has also been shown to decrease risk of developing AD as well as 
cerebrovascular disease (5-6, 8). The Finnish Geriatric Intervention Study to Prevent Cognitive 
Impairment and Disability (FINGER), a two year randomized controlled trial, found a positive 
effect of the multicomponent intervention on change in cognitive function reinforcing the 
importance of a shift towards holistic, multimodal interventions aimed at modifying risk factors 
that occur throughout the life course. Furthermore, behavioral interventions and graduated 
care plans typically are more successfully implemented at earlier stages of AD (7-9). 
Primary care providers are typically the front lines of dementia care and often the first point of 
contact for patients with concerns about cognitive function. Despite this, fewer than half of all 
patients with dementia carry a diagnosis in their medical record (1). Physicians are often the 
most familiar with the longitudinal health and functioning of their patients, making them 
uniquely suited to screen patients for dementia. However, limited appointment time, unwieldy 
screening tools and workflow disruption remain significant barriers to regular screening.  To 
best utilize primary care settings for dementia screenings, a brief, easy to administer, and 
psychometrically robust screening tool is needed.  Tools also need to be embedded within 
streamlined evidence based processes facilitating early detection and diagnosis (10). 
The purpose of this paper is to provide guidance for detection of cognitive impairment in 
primary care settings, thereby promoting early detection of MCI and dementia.  Consistent with 
the goals of the Washington State Plan to Address Alzheimer's Disease and Other Dementias, 
this paper seeks to promote setting-appropriate, evidence-based best practices around 
opportunities for case finding and detection, cognitive screening tools, and care pathways for 
patients with cognitive impairment.   
 
Opportunities for Screening 
Several primary care encounters provide opportunity for screening and detection/case finding 
for cognitive impairment. These include visits or occasions when patients or families: 
 Present with concerns or evidence of cognitive impairment 
 Have completed either online or community-based cognitive assessments; given 
variability in administration, measures used and in the absence of additional medical 
information, these results may shape provider interests in completing more formal 
evaluation within the primary care environment 
 Present for a Welcome to Medicare or Medicare Annual Wellness Visit, for which 
cognitive screening is also a covered component 
 Have increased risk for cognitive impairment, including the presence of significant 
vascular risk factors and middle age, significant family history of cognitive impairment, 
 
November 2017                    www.dshs.wa.gov/altsa/stakeholders/alzheimers-state-plan                     Page 3 of 10 
 
or presence of other medical comorbidities associated with increased risk for cognitive 
impairment such as brain injury, sleep apnea, psychiatric conditions, polypharmacy, or 
metabolic syndrome.   
While global cognitive screening remains an aspirational goal, implementation of more regular 
assessment of at risk populations would be an important first step. 
 
Screening Recommendations  
Consistent with the recent review by the Medicare Detection of Cognitive Impairment 
Workgroup recommendations (10), the Dementia Action Collaborative supports a model to rely 
on objective data around cognitive functioning from patients and collateral informants.  Given 
the unique demands and constraints of the primary care visit, objective screening measures 
must balance adequate sensitivity, specificity and other psychometric properties with ease of 
administration, ensuring congruency with operators and context that influences workflow.  In 
addition, the high prevalence of hearing loss in older adults may complicate identification and 
or treatment as cognitive testing and follow up often relies heavily on a person’s ability to hear 
and respond to questions and instructions. It is recommended that providers initially assess for 
sensory loss, provide appropriate treatment or referrals for additional diagnostic evaluation, 
and provide in-clinic assistive devices (e.g., Pocket Talker1) before any assessment of cognition 
is undertaken. There are a variety of screening tools and tests for hearing loss available for self-
administration or use by non-hearing professionals2. 
Once sensory issues have been assessed and addressed, the clinician is faced with selection of 
the appropriate tool for their individual setting and patient. While the Mini-mental State 
Examination (11) continues to be a frequently used tool, myriad studies outline the suboptimal 
psychometric properties and the currently charged fees for each administration are barriers for 
frequent usage.  Alternatively, the Montreal Cognitive Assessment (MoCA; 12) yields superior 
sensitivity and specificity in detecting dementia and MCI and remains the gold standard in 
relatively brief screening instruments. The MoCA is among the best validated cognitive 
screening tools, particularly for individuals with mild impairments (11). The test assesses 8 
domains of cognitive functioning: attention and concentration, executive functions, memory, 
language, visuoconstructional skills, conceptual thinking, calculations, and orientation and 
requires about 10 to 15 minutes to administer. The measure is psychometrically robust, 
including high test-retest reliability, internal consistency and content validity. The MoCA has 
                                                        
1 “Pocket talkers” and other hand-held personal hearing amplifiers are small portable devices consisting of a 
microphone and sound amplifier, which connect to headphones or earbuds. They are key to communication 
with persons with hearing loss, who do not wear hearing aids.     
2 For further information contact the Hearing Loss Association of Washington at: info@hearingloss-wa.org 
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also been translated into many languages and is available in multiple alternate forms with no 
usage fee. 
The MoCA’s 15-minute administration time is typically prohibitive for implementation in 
primary care settings but may be an optimal tool for a more detailed visit dedicated to 
thorough assessment of cognitive function. A more ideal screening tool for a primary care 
environment would reduce the administration time of the MoCA while providing comparable 
psychometric properties, including sensitivity and specificity to MCI and AD profiles. As outlined 
in the review by Cordell and colleagues, three no-cost measures appear well suited for 
implementation in primary care visits, including but not limited to the Medicare Annual 
Wellness Visit.  For the patient, these include: 
A. General Practitioner Assessment of Cognition (GPCOG; 13), which is a multi-
dimensional screening tool assessing memory, orientation and aspects of both 
visuospatial and executive function as well as informant receptions of cognitive and 
functional changes.  Administration time is 2-5 minutes for the patient and one to 3 
minutes for the informant with adequate psychometrics, minimal training needs, as 
well as online administration and training in multiple languages 
(http://gpcog.com.au/). The GPCOG can be administered by a variety of operators 
including medical assistants, nursing staff and providers.  While there appears to be 
little to no education bias, there is currently no data on bias related to language or 
cultural factors. Scores less than 5 are considered abnormal, with scores from 5-8 
indeterminate and requiring either further assessment or corroboration from a 
collateral informant. 
B. Mini-Cog (14), which assesses memory and components of visuospatial and 
executive functioning.  Administration time is approximate 2-3 minutes with a well-
codified scoring algorithm.  Psychometric properties are adequate for dementia, 
although reduced with mild cognitive impairment. The Mini-Cog can be 
administered by a variety of operators including medical assistants, nurses and other 
providers, with online training available (http://mini-cog.com/). This measure was 
developed for and validated in primary care settings and is available in multiple 
languages with little to no education, language or cultural bias.  Scores less than or 
equal to 3 are considered indicative of impairment. 
C. Memory Impairment Screen (MIS; 15), which assesses verbal memory only, albeit 
with greater depth involving free versus cued recall and no demands on writing or 
motor function.  Administration time is approximately 4 minutes, half of which is a 
distractor activity where other clinical data can be obtained. Psychometric 
properties are adequate with clear scoring criteria. The MIS can be administered by 
a variety of operators with minimal training needs 
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(http://www.alz.org/documents_custom/mis.pdf). There appears to be little to no 
education bias however lack of assessment of executive functioning are visuospatial 
skills may decrease sensitivity and specificity, particularly in mild cognitive 
impairment.  Scores less than or equal to 4 are considered indicative of impairment. 
Screening measures for care partners or family members include: 
A. GPCOG, informant version ((http://gpcog.com.au/) administered in conjunction with 
patient version, given that the informant version alone yields low specificity.  
Administration time is approximately 2 minutes with a score less than or equal to 3 
considered indicative of impairment. 
B. Family Questionnaire (http://www.actonalz.org/pdf/Family-Questionnaire.pdf).  
Brief tool consisting of 6 questions obtaining a family member’s insights on the 
individual’s cognitive functioning.  Administration time is 3 minutes and a score of 3 
or greater suggest the need for additional evaluation.   
C. AD8 Dementia Screening Interview (http://alz.org/documents_custom/ad8.pdf)  
(16). Assesses change in function and activity secondary to cognitive impairment 
with self-administration, in person and telephone options. Adequate sensitivity and 
specificity for dementia although slightly reduced for mild cognitive impairment.  
Administration time is approximately 2 minutes with a score of 2 or greater 
considered indicative of impairment.  
D. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE; 17). 
(https://www.alz.org/documents_custom/shortiqcode_english.pdf). Requires more 
extensive knowledge of the individual (ideally 10 years or more) as well as 10-15 
minutes of administration time and slightly more complex scoring. Benefits include 
adequate sensitivity and specificity for dementia, but suboptimal in MCI (.46). 
Published in multiple languages with a score of greater than or equal to 3.38 
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Table 1.  Screening Measures Matrix – Patient and Informant Versions 
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Outcome Pathways 
Clinical best practices would include integration of cognitive screening tools/results with the 
electronic medical record, thus serving as a trackable health metric. Once cognitive screening 
has been completed, results may be entered as a baseline cognitive vital sign for continued 
assessment. Individuals with notable cognitive concerns or suspected cognitive impairment not 
detected by screening may return to clinic at a later time for more detailed assessment with the 
MoCA or other similar measure. Individuals with borderline scores may be retested at 
subsequent visits or intervals. With appropriate tools and protocols, the vast majority of cases 
can be detected and managed within the primary care setting.  Cases with atypical 
presentations (i.e. young age of onset, complex neuropsychiatric symptoms, probable mixed 
etiologies) may trigger referral for detailed evaluation by a specialist, including neurology 
(particularly behavioral neurologist if available), psychiatry (particularly geriatric if available), 
neuropsychologist, or comprehensive memory clinic. Individuals with significant impairment 
and relatively uncomplicated presentations may garner a diagnosis at the point of initial 
evaluation in the primary care setting with consideration of further standard of care workup 
such as chemistries and imaging as indicated and endorsed as evidence-based best practices 
(see Bree Collaborative Workgroup for Alzheimer's/Dementia Guidelines). 
Consistent with best practices models, detection of cognitive impairment and/or dementia 
would result in early referrals to community resources such as the Alzheimer’s Association, 
Alzheimer Society of Washington, Area Agencies on Aging, early stage support groups, 
programs such as Momentia, and other community supports and services outlined in additional 
components of the Washington State Plan. 
 
Summary/Conclusions 
Given significant increases in the prevalence of cognitive impairment, including mild cognitive 
impairment and dementia, as well as increases in medical comorbidities which serve as risk 
factors, early detection and diagnosis presents as a critical issue facing primary care providers in 
Washington State.  In order to address the gaps and challenges faced by providers, the 
Dementia Action Collaborative promotes the following framework: 
1) Detection at early stages provides both a window of opportunity for risk reduction as 
well as a longer duration for education, planning and access to treatments and 
community resources which in turn improves dementia care and quality of life.  
2) Primary care providers have been identified as the first point of contact for patients and 
families concerned about changes in cognition and are uniquely situated to detect, 
diagnose and care for individuals with cognitive impairment.  
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3) While no one screening tool or care pathway will work for all organizations, clinics or 
individual providers, the Dementia Action Collaborative (DAC) strongly supports 
implementation of objective screening protocols and pathways as a general process.  
Furthermore, it seeks to provide the support and training to guide those on the front 
lines.   
4) Linking rural and community primary care providers and frontline staff to 
multidisciplinary specialists with expertise in the diagnosis, risk reduction and 
management of dementia can improve early detection and treatment. Through the DAC 
initiative, physicians, advanced nurse practitioners and medical staff from rural and 
underserved communities will also have the opportunity to present challenging cases 
for discussion, to identify key focus areas and discuss specific recommendations to 
achieve an optimal care plan.    
5) Living with or caring for someone with dementia can be challenging, and with the right 
supports and tools deeply gratifying. The skills and knowledge gained will help preserve 
the quality of life for these individuals by giving the health professionals who care for 
them access to didactics and case-presentation curriculum created with the best 
evidence. The curriculum will include topics on common issues in the geriatric patient 
population such as: the diagnosis and management of dementia and delirium, agitated 
and psychotic behaviors, depression, functional decline, falls, and polypharmacy. 
Determination of the specifics within these processes rests with providers and health 
care systems in response to the unique needs of their patients and families. 
 
This paper was authored and edited by:  
Kristoffer Rhoads, PhD, Nancy Isenberg, MD, MPH, FAAN, Lynne Korte, MPH, on behalf of the 
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